Arthur Penn
Analyst · JMP Securities
Thanks, Aviv. First, we hope that you, your families and those you work with are staying healthy. I'm going to spend a few minutes discussing how we fared in the quarter ended December 31, how the portfolio is positioned for the upcoming quarters, our capital structure and liquidity, the financials and then open it up to Q&A.
Despite the challenging economic conditions brought on by the pandemic, we are pleased with our performance this past quarter. We achieved another substantial increase in NAV during the quarter. Adjusted NAV increased 4.3% from $11.81 to $12.32 as our portfolio continued to improve during the quarter. We have several portfolio companies in which our equity co-investments have materially appreciated in value and we are benefiting from the K-shaped recovery, which is solidifying and bolstering our NAV. Over time, rotation of that equity into debt instruments should help grow PFLT's income. We will highlight those companies in a few minutes.
As part of our business model, alongside the debt investments we make, we selectively choose to co-invest in the equity side-by-side with the financial sponsor. Our returns on these equity co-investments have been excellent over time. Overall for our platform from inception through December 31, our $217 million of equity co-investments have generated an IRR of 28% and a multiple on invested capital of 2.9x. In a world where investors may want to understand differentiation among middle market lenders, our long-term returns on our equity co-investment program are a clear differentiator.
Additionally, in late December, we priced a CLO financing in our PSSL JV, which closed in late January. We've been pleased with the stable performance of PFLT's long-term low-cost securitization CLO financing through COVID. This type of financing is well matched to finance our senior debt positions, which we believe are among the lowest risk in the industry. As a result of the completion of this CLO financing of PSSL, we can efficiently grow the venture, which should generate additional income for PFLT. The combination of potential income growth from equity rotation, a larger and more efficiently financed PSSL and a growing more optimized PFLT balance sheet should help grow the company's net investment income relative to its dividend over time. Those factors, combined with strong portfolio performance through COVID and our $0.22 spillover as of September 30, have led us to conclude that we will be keeping our dividend steady at this point.
Although we never predicted a global pandemic, as you may know, we have been preparing for an eventual recession for some time. Prior to the COVID-19 crisis, we proactively positioned the portfolio as defensively as possible. Since inception, we had a portfolio that was among the lowest risk in the direct lending industry. As of December 31, average debt-to-EBITDA in the portfolio was 4x and the average interest coverage ratio, the amount by which cash income exceeds cash interest expense, was 2.9x. This provides significant cushion to support stable investment income. These statistics are among the most conservative in the direct lending industry.
We have only 2 nonaccruals out of 105 different names in PFLT and PSSL. This represents only 2.3% of the portfolio cost and 1.9% at market value. We have largely avoided some of the sectors that have been hurt the most by the pandemic, such as retail, restaurants, health clubs, apparel and airlines. PFLT also has no exposure to oil and gas. The portfolio is highly diversified with 100 companies in 42 different industries. Our credit quality since inception over 9 years ago has been excellent. Out of 387 companies in which we have invested since inception, we have experienced only 13 nonaccruals. Since inception, PFLT has invested over $3.7 billion at an average yield of 8.1%. This compares to an annualized realized loss ratio of only 10 basis points annually. If we include both realized and unrealized losses, the underlying loss ratio is only 12 basis points annually.
We are one of the few middle-market direct line issuers in business prior to the global financial crisis and have a strong underwriting track record during that time. Although PFLT was not in existence back then, PennantPark as an organization was investing at that time. During that recession, our weighted average EBITDA of our underlying portfolio companies declined by 7.2% at the bottom of the recession. This compares to the average EBITDA decline of the Bloomberg North America High Yield Index of negative 42%. And we are proud of this downside case track record in the prior recession.
Based on tracking EBITDA of our underlying companies through COVID so far, we believe that our EBITDA decline will be substantially less than it was during the global financial crisis.
Looking forward to 2021, where things stand today, our analysis suggests that the vast majority of the companies in our portfolio are in a strong position to perform well in the coming quarters. Many of our portfolio companies are in industries such as government services defense, healthcare, technology software, business services and select consumer companies that are less impacted by COVID and where we have meaningful domain expertise. We believe that we are experiencing a K-shaped recovery with some companies and industries being large beneficiaries of the environment. We are pleased that we have significant equity investments in 3 of these companies, which can substantially move the needle in both NAV and, over time, net investment income.
I would like to highlight these 3 companies. The 3 companies are Cano, Walker Edison and By Light. Cano Health is a national leader in primary health care and is leading the way in transforming health care to provide high-quality care at a reasonable cost to a large population. Our equity position has a cost and market value on December 31 of $431,000 and $9.1 million, respectively. Cano has been experiencing rapid growth with revenues nearly quintupling and EBITDA more than tripling over the last 3 years. We believe that there is a massive market opportunity for Cano to grow in the years ahead with the Medicare Advantage program. During the quarter ended December 31, we received $200,000 of cash as a return of capital. The merger with Jaws Acquisition is scheduled to close at the end of March or early April. At that time, we will receive another $800,000 of cash and own 825,274 shares of Cano Health in a limited partnership controlled by a financial sponsor, where the sponsor will own 20% of the exit proceeds. The shares will be locked up for 6 months. From a valuation perspective, due to the lockup, the independent valuation firm valued the position with a 7% illiquidity discount to the traded value on December 31.
Walker Edison is a leading e-commerce platform focused on selling furniture exclusively online through top e-commerce companies. Since our investment was made in 2018, sales have more than tripled, and EBITDA is up almost 4x. Our position has a cost of $1.4 million and a fair market value of $11.1 million as of December 31.
By Light is a leading software, hardware and engineering solutions company focused on national security challenges across modeling and simulation, cyber and global defense networks. Since our initial investment was made nearly 4 years ago, sales have gone up 1.5x, and EBITDA has more than doubled. Our position has a cost of $2.2 million and a fair market value of $10.8 million as of December 31.
All 3 of these companies are gaining financial momentum in this environment, and our NAV should be solidified and bolstered from these substantial equity investments as our momentum continues. Over time, we expect to execute positions and rotate those proceeds into debt instruments to increase income at PFLT.
We were active this past quarter making new loans. I'll walk through some of the highlights. We purchased $15 million of the first-lien term loan of the Aegis Technologies Group. The company is a government contractor, providing differentiated solutions across space superiority, directed energy and missile defense. Arlington Capital Partners is the sponsor.
Applied Technical Services is a provider of nondestructive testing, calibration lab and consulting engineering services. We purchased $9.5 million of first-lien term loan and co-invested $504,000 of common equity. [ ISC Investment Partners ] is the sponsor. Hancock Claims Consultants is a leading insurance claims services company focused on the residential roofing market on behalf of carriers. We purchased $6 million of the term loan and $450,000 of equity. Century Equity Partners is the sponsor.
Rancho Health is a primary care provider in Southern California that is focused on offering value-based primary care. We purchased $3.7 million of first-lien term loan and co-invested $1.1 million of common equity. LightBay Capital is the sponsor. Sigma Defense Systems is a leading IT services provider and systems integrator of satellite communication equipment for mission-critical airborne surveillance programs. We purchased $7.5 million of first-lien term loan and purchased 642,000 common equity for Sigma Defense systems. Sagewind Capital is the sponsor.
The outlook for new loans is attractive. We believe our middle-market lending is a vintage business. This upcoming vintage of loans is likely to be the most attractive we've seen since the 2009 to 2012 time period. The leverage levels are lower, equity cushion is higher, yields are higher and the package of protections, including covenants are tighter. After enduring about 5 years of a late-cycle market in the middle-market lending, it's refreshing to have attractive risk reward available to us.
Let me now turn the call over to Aviv, our CFO, to take us through the financial results in more detail.